




Registration and Stamp Department  
Madhya Pradesh



Certificate of Stamp Duty

E-Stamp Details

E-Stamp Code 01011714092023012525  
Total E-Stamp Amount 500  
Govt. Stamp Duty (Rs.) 500 Municipality Duty (Rs.) 0  
Janpad Duty (Rs.) 0 Upkar Amount (Rs.) 0  
Exempted Amount(Rs.) 0  
E-Stamp Type NON-JUDICIAL  
Issue Date & Time 14/09/2023 16:33:17  
Service Provider or Issuer Details BHAVANA THAKUR/SP011743311201600148  
SP/SRO/DRO/HO Details 281-282 Sawariya Nagar Chhota Bangarda Road INDORE INDORE

Deed Details

Deed Type Agreement or Memorandum of an agreement  
Deed Instrument If not otherwise provided for- Five hundred rupees.  
Purpose UNDERTAKING

First Party Details

Organization Name Zenith Drugs Limited  
Address STAMP PRINT IN INDORE Madhya Pradesh INDIA  
Number of Persons 1

Second Party Details

Organization Name Gretex Corporate Services Limited  
Address STAMP PRINT IN INDORE Madhya Pradesh INDIA  
Number of Persons 1


THIS E-STAMP IS FOR UNDERTAKING

For Zenith

Limited  
Director



Digitally signed by  
BHAVANA THAKUR  
Date: 2023.09.14 16:33:19  
IST



**ADDENDUM TO UNDERWRITING AGREEMENT**

**THIS DOCUMENT IS EXECUTED ON JANUARY 24, 2024 IN REFERENCE TO UNDERWRITING AGREEMENT DATED SEPTEMBER 25, 2023 BETWEEN THE FOLLOWING PARTIES THAT ARE NAMED BELOW THIS DOCUMENT:**

**ZENITH DRUGS LIMITED** a Company incorporated under the Companies Act, 1956 and having its Registered Office at K. No. 72/5, Village Muradpura, NA Depalpur, Indore Madhya Pradesh, 453001 India. (hereinafter referred to as **"the Company"/ "the Issuer Company"/ "Issuer"/ "ZENITH"**) which expression shall, unless it be repugnant to the context or meaning thereof, be deemed to mean and include its successors and permitted assigns, of the **FIRST PART**

**AND**

**GRETEX CORPORATE SERVICES LIMITED (FORMERLY KNOWN AS GRETEX CORPORATE SERVICES PRIVATE LIMITED) (GRETEX)**, a company incorporated under the Companies Act, 1956 and having its office at A-401, Floor 4th, Plot FP-616, (PT), Naman Midtown, Senapati Bapat Marg, Near Indiabulls, Dadar (w), Delisle Road, Mumbai-400013 Maharashtra, India. (hereinafter referred to as **"GRETEX"** or **"Book Running Lead Manager"**) which expression shall, unless it be repugnant to the context or meaning thereof, be deemed to mean and include its successors and permitted assigns, of the **SECOND PART**

**AND**

**GRETEX SHARE BROKING LIMITED (FORMERLY KNOWN AS GRETEX SHARE BROKING PRIVATE LIMITED)**, a Company incorporated under the Companies Act, 1956 and having its Registered Office at A-401, Floor 4th, Plot FP-616, (PT), Naman Midtown, Senapati Bapat Marg, Near Indiabulls, Dadar (w), Delisle Road, Mumbai-400013 Maharashtra, India. (hereinafter referred to as **"GSBL"** or **"Market Maker"** which expression shall, unless it be repugnant to the context or meaning thereof, be deemed to mean and include its successors and permitted assigns) of the **THIRD PART**

In this Underwriting Agreement, the **ZENITH, GRETEX and GSBL** are collectively referred to as **"Parties"** and individually as **"Party"**.

**AMENDMENT TO THE AGREEMENT**

**WHEREAS:**

- A. The Issuer Company proposes to Issue upto 51,48,800 of equity shares the Company in accordance with the Companies Act, 2013, the SEBI (ICDR) Regulations, 2018 as amended and other applicable Indian securities laws at such price as may be determined through book building process under the SEBI ICDR Regulations

For Zenith Drugs Limited	For Gretex Corporate Services Limited	For Gretex Share Broking Limited
<p>For Zenith Drugs Limited,  Director. Sandeep Bhardwaj Managing Director DIN: 00539347</p>	<p>Arvind Harlalka  Director DIN: 00494136</p> 	<p>Arvind Harlalka  Managing Director DIN: 00494136</p> 

(the "Issue Price"). The shares are proposed to be offered to the public under Regulation 229(2) of Chapter IX of SEBI (ICDR) Regulations, 2018 via Book Built Process.

- B. The Equity Shares issued to the public of upto 51,48,800 of the face value of Rs. 10.00 each, and a reserved portion for the Designated Market Maker of upto 8,52,800 Equity Shares of the face value of Rs. 10.00 each (the "Market Maker Reservation Portion"), (the "Issue"). The net offer to public shall comprise of offer to Retail Investors, Individual Applicants other than Retail Individual Investors and other Investors including corporate bodies or institutions irrespective of the number of specified Equity Shares applied for.

**NOW, THEREFORE IT IS HEREBY AGREED BY AND AMONG THE PARTIES HERETO AS FOLLOWS:**

**1. DEFINITIONS AND INTERPRETATIONS**


"Fresh Issue" shall mean issue of upto 51,48,800 Equity Shares.


**2. UNDERWRITING**



2.1 Following will be the underwriting obligations of each respective under:



Name of the Underwriter	No. of shares Underwritten	% of the Total Issue Size Underwritten
Gretex Corporate Services Limited	25,74,400	50
Gretex Share Broking Limited	25,74,400	50
<b>Total</b>	<b>51,48,800</b>	<b>100.00</b>

**IN WITNESS WHEREOF** the Parties have entered into this Agreement on the date mentioned above.

For and on behalf of <b>Zenith Drugs Limited</b>  <b>Sandeep Bhardwaj</b> Managing Director DIN: 00539347	<b>Witness</b> Name: <i>Nikhil Patel</i> Address: <i>Block G, Sree Ram Colony, Rau, Indore</i> Signature: <i>N Patel</i>
---	---


For Zenith Drugs Limited For Zenith Drugs Limited,  Director. <b>Sandeep Bhardwaj</b> Managing Director DIN: 00539347	For Gretex Corporate Services Limited   <b>Arvind Harlalka</b> Director DIN: 00494136	For Gretex Share Broking Limited   <b>Arvind Harlalka</b> Managing Director DIN: 00494136
--	---	--

<p>For and on behalf of GreteX Corporate Services Limited</p> <p><i>Arvind Haralka</i></p> <p>Arvind Haralka Director DIN: 00494136</p> 	<p>Witness Name: <i>Rudhant More</i> Address: <i>Mumbai</i> Signature: <i>Rudhant</i></p>
<p>For and on behalf of GreteX Share Broking Limited</p> <p><i>Arvind Haralka</i></p> <p>Arvind Haralka Managing Director DIN: 00494136</p> 	<p>Witness Name: <i>Susga Kant</i> Address: <i>Mumbai</i> Signature: <i>Susga</i></p>

<p>For Zenith Drugs Limited</p> <p><i>Sandeep Bhardwaj</i></p> <p>Sandeep Bhardwaj Managing Director DIN: 00539347</p>	<p>For GreteX Corporate Services Limited</p> <p><i>Arvind Haralka</i></p> <p>Arvind Haralka Director DIN: 00494136</p> 	<p>For GreteX Share Broking Limited</p> <p><i>Arvind Haralka</i></p> <p>Arvind Haralka Managing Director DIN: 00494136</p> 
--	---	--



Registration and Stamp Department  
Madhya Pradesh



Certificate of Stamp Duty


	<b>E-Stamp Details</b>	
E-Stamp Code	01011714092023009372	
Total E-Stamp Amount	600	
Govt. Stamp Duty (Rs.)	600	Municipality Duty (Rs.) 0
Janpad Duty (Rs.)	0	Upkar Amount (Rs.) 0
Exempted Amount(Rs.)	0	
E-Stamp Type	NON-JUDICIAL	
Issue Date & Time	14/09/2023 15:02:57	
Service Provider or Issuer Details	BHAVANA THAKUR/SP011743311201600148	
SP/SRO/DRO/HO Details	281-282 Sawariya Nagar Chhota Bangarda Road INDORE INDORE	
	<b>Deed Details</b>	
Deed Type	Agreement/Memorandum of an agreement	
Deed Instrument	If relating to secure repayment of a loan or debt.- 0.25 percent of the amount of loan or debt, subject to a maximum of five lakh rupees	
Purpose	AGREEMENT	
	<b>First Party Details</b>	
Organization Name	Zenith Drugs Limited	
Address	STAMP PRINT IN INDORE Madhya Pradesh INDIA	
Number of Persons	1	
	<b>Second Party Details</b>	
Organization Name	Gretex Corporate Services Limited	
Address	STAMP PRINT IN INDORE Madhya Pradesh INDIA	
Number of Persons	1	

THIS E-STAMP IS FOR AGREEMENT

**For Zenith Drugs Limited**  
*[Signature]*  
**Director.**



Digitally signed by  
BHAVANA THAKUR  
Date: 2023.09.14 15:02:58  
IST



**UNDERWRITER AGREEMENT FOR INITIAL PUBLIC OFFERING (IPO) BY ZENITH DRUGS LIMITED**

This Underwriter Agreement is made and entered into at Indore on this September 25, 2023 between:

**ZENITH DRUGS LIMITED** a Company incorporated under the Companies Act, 1956 and having its Registered Office at K. No. 72/5, Village Muradpura, NA Depalpur, Indore Madhya Pradesh, 453001 India. (hereinafter referred to as "the Company"/ "the Issuer Company"/ "Issuer"/ "ZENITH") which expression shall, unless it be repugnant to the context or meaning thereof, be deemed to mean and include its successors and permitted assigns, of the **FIRST PART**

AND

**GRETEX CORPORATE SERVICES LIMITED (FORMERLY KNOWN AS GRETEX CORPORATE SERVICES PRIVATE LIMITED) (GRETEX)**, a company incorporated under the Companies Act, 1956 and having its office at Office No. 13, 1st Floor, New Bansilal Building, Raja Bahadur Mansion, 9-15, Homi Modi Street, Fort, Mumbai- 400001, Maharashtra, India (hereinafter referred to as "GRETEX" or "Book Running Lead Manager" which expression shall, unless it be repugnant to the context or meaning thereof, be deemed to mean and include its successors and permitted assigns, of the **SECOND PART**




AND

**GRETEX SHARE BROKING LIMITED**, a Company incorporated under the Companies Act, 1956 and having its Registered Office at A-401, Floor 4th, Plot FP-616, (PT), Naman Midtown, Senapati Bapat Marg, Near Indiabulls Dadar (w) S V S Marg Mumbai 400028, Maharashtra, India (hereinafter referred to as "GSBL" or "Market Maker" which expression shall, unless it be repugnant to the context or meaning thereof, be deemed to mean and include its successors and permitted assigns) of the **THIRD PART**

In this Underwriting Agreement, the ZENITH, GRETEX and GSBL are collectively referred to as "Parties" and individually as "Party".

**WHEREAS:**

- A. The Issuer Company proposes to Issue upto 42,92,000 of equity shares the Company in accordance with the Companies Act, 2013, the SEBI (ICDR) Regulations, 2018 as amended and other applicable Indian securities laws at such price as may be determined through book building process under the SEBI ICDR Regulations (the "Issue Price"). The shares are proposed to be offered to the public under Regulation 229(2) of Chapter IX of SEBI (ICDR) Regulations, 2018 via Book Built Process.
- B. The Equity Shares issued to the public of upto 42,92,000 of the face value of Rs. 10.00 each, and a reserved portion for the Designated Market Maker of upto [•] Equity Shares of the face value of Rs. 10.00 each (the "Market Maker Reservation Portion"), (the "Issue"). The net offer to public shall comprise of offer to Retail Investors, Individual Applicants other than Retail Individual Investors and other Investors including corporate bodies or institutions irrespective of the number of specified Equity Shares applied for.
- C. The Issuer Company has obtained approval for the Issue pursuant to the Board resolution dated September 16, 2023. The Issuer Company passed a special resolution under section 62 (1) (C) at the Extra Ordinary General Meeting held on September 16, 2023.

<p>For Zenith Drugs Limited <b>For Zenith Drugs Limited.</b></p>  <p>Director.</p> <p>Sandeep Bhardwaj Managing Director DIN: 00539347</p>	<p>For Gretex Corporate Services Limited</p>  <p>Alok Harlalka Managing Director DIN: 02486575</p>	<p>For Gretex Share Broking Limited</p>  <p>Alok Harlalka Director DIN: 02486575</p>
---	--	---

- D. One of the requirements of issuing shares to the Public in accordance with the Chapter IX of the SEBI (ICDR) Regulations, 2018, as specified in Regulation 260 of the said Regulations is that the Issue shall be hundred percent underwritten and that the Book Running Lead Manager shall underwrite at least 15% of the total issue, GRETEX being the Book Running Lead Manager to the Issue.
- E. The Issuer Company has approached GRETEX for being appointed as Book Running Lead Manager, and Underwriter and GSBL for being appointed as Underwriter and Market Maker for this Public Issue. GRETEX and GSBL has accepted such proposal and confirm that there is no conflict of interest arising from such transaction or arrangement.
- F. Hence, GRETEX and GSBL shall act as Underwriters to this Issue and all the parties herein have therefore agreed to enter into this agreement for the purpose of underwriting and amongst the other things as required under regulation 14 of SEBI (Underwriters) Regulations 1993.

**NOW, THEREFORE IT IS HEREBY AGREED BY AND AMONG THE PARTIES HERETO AS FOLLOWS:**

**1. DEFINITIONS AND INTERPRETATIONS**

1.1 In addition to the defined terms contained elsewhere in the Agreement, the following expressions, as used in this Agreement, shall have the respective meanings set forth below:

“**Affiliates**” with respect to any person means (a) any persons that directly or indirectly, through one or more intermediaries, control or are controlled by or are under common control with, the specified person.

“**Allotment**” shall mean the Issue and allotment of Equity Shares pursuant to successful applicants.

“**Agreement**” shall mean this agreement or any other agreement as specifically mentioned.




“**Applicant**” shall mean any prospective investor who makes an application for Equity Shares in terms of the Draft Red Herring Prospectus or Red Herring Prospectus or Prospectus.

“**Application**” shall mean an indication to make an Application during the application period by a prospective investor at the Issue price, including all revisions and modifications thereto.

“**Bid/Issue Closing Date**” shall mean except in relation to Anchor Investors, any such date on completion of the application hours after which the Designated Intermediaries will not accept any Bids for the Issue which shall be the date notified in a widely circulated English national newspaper and a Hindi national newspaper and a regional newspaper.

“**Bid/Issue Opening Date**” shall mean, except in relation to Anchor Investors, any such date on which the Designated Intermediaries shall start accepting Bids for the issue, within the application hours which shall be the date notified in a widely circulated English national newspaper and a Hindi national newspaper and a regional newspaper.

“**Bid/Issue Period**” shall mean, except in relation to Anchor Investors, the period between the Bid/Issue Opening Date and the Bid/Issue Closing Date, inclusive of both days, during which Bidders can submit their Bids, including any revisions thereof;

<p>For Zenith Drugs Limited <b>For Zenith Drugs Limited.</b></p>  <p><b>Director.</b></p> <p>Sandeep Bhardwaj Managing Director DIN: 00539347</p>	<p>For Gretex Corporate Services Limited</p>  <p>Alok Harlalka Managing Director DIN: 02486575</p>	<p>For Gretex Share Broking Limited</p>  <p>Alok Harlalka Director DIN: 02486575</p>
--	--	---

“Bid” shall mean an indication to make an offer during the Bid/Issue Period by an ASBA Bidder pursuant to submission of the ASBA Form, or during the Anchor Investor Bid/Issue Period by an Anchor Investor, pursuant to submission of the Anchor Investor Application Form, to subscribe to or purchase the Equity Shares at a price within the Price Band, including all revisions and modifications thereto as permitted under the ICDR Regulations and in terms of the Red Herring Prospectus and the Bid cum Application Form. The term “Bidding” shall be construed accordingly;

“Bid Amount” shall mean the highest value of optional Bids indicated in the Bid cum Application Form and, in the case of RIBs Bidding at the Cut off Price, the Cap Price multiplied by the number of Equity Shares Bid for by such Retail Individual Bidder and mentioned in the Bid cum Application Form and payable by the Bidder or blocked in the ASBA Account of the Bidder, as the case may be, upon submission of the Bid;

“Bid cum Application Form” shall mean the Anchor Investor Application Form or the ASBA Form, as the context requires;

“Book Running Lead Manager” or “BRLM” shall mean Gretex Corporate Services Limited;

“Companies Act” shall mean the Companies Act, 2013, as amended from time to time.

“Controlling”, “Controlled by” or “Control” shall have the same meaning prescribed to the term “control” under the SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011, or as amended.

“Controlling Person(s)” with respect to specified person, shall mean any other person who Controls such specified person.

“Draft Red Herring Prospectus” shall mean the Draft Red Herring Prospectus dated [●] issued in accordance with the ICDR Regulations, which did not contain complete particulars of the price at which the Equity Shares will be Allotted.;

“EMERGE Platform of NSE Limited” shall mean the separate platform for listing company which have issued shares/or whose shares have been offered or match the relevant criteria of Chapter IX of the SEBI (ICDR) Regulation 2018, as amended from time to time.




“Fresh Issue” shall mean issue of upto 42,92,000 Equity Shares.

“Public Issue Account” shall mean the bank account opened with the Public Issue Account Bank under Section 40(3) of the Companies Act, 2013 to receive monies from the Escrow Accounts and the ASBA Accounts on the Designated Date;

“Indemnified Party” shall have the meaning given to such term in this Agreement.

“Indemnifying Party” shall have the meaning given to such term in this Agreement.

“Issue Agreement” shall mean agreement dated September 25, 2023 between Book Running Lead Manager, the issuer company.

<p>For Zenith Drugs Limited <b>For Zenith Drugs Limited,</b>  Director. Sandeep Bhardwaj Managing Director DIN: 00539347</p>	<p>For Gretex Corporate Services Limited  Alok Harlalka Managing Director DIN: 02486575</p>	<p>For Gretex Share Broking Limited  Alok Harlalka Director DIN: 02486575</p>
---	---	--



“Offer Documents” shall mean the Draft Red Herring Prospectus, the Red Herring Prospectus, the Prospectus, the Bid cum Application Form including the abridged prospectus, the Confirmation of Allocation Notes, the Allotment Advice and any amendments, supplements, notices, corrections or corrigenda to such offering documents;

“Issue Price” shall mean the final price at which Equity shares will be allotted in terms of the Red Herring Prospectus, the Issue price will be decided by our company in consultation with BRLM on the pricing date in accordance with the Book Building Process and the Red Herring Prospectus.

“Market Maker Reservation Portion” shall be not be less than 5% of shares offered under the IPO as required as per Regulation 261, sub regulation (4) of SEBI (ICDR) Regulations.

“Material Adverse Effect” shall mean, individually or in the aggregate, a material adverse effect on the condition, financial or otherwise, or in the earnings, business, management, operations or prospects of the Company and its subsidiaries, taken as a whole.

“Net Offer” shall mean Issue of equity shares in the Issue excluding Market Maker Reservation Portion.

“Non-Institutional Applicants” shall mean all bidders other than QIBs or Retail Applicants and who have applied for Equity shares for an amount more than Rs. 2,00,000.

“NSE” shall mean NSE Limited.

“Offer Document” shall mean and include the Draft Red Herring Prospectus and the Prospectus as and when approved by the Board of Directors of Issuer Company and filed with EMERGE Platform of National Stock Exchange of India Limited.

“Party” or “Parties” shall have the meaning given to such terms in the preamble to this Agreement.

“Prospectus” shall mean the prospectus to be filed with the RoC on or after the Pricing Date in accordance with Section 32 of the Companies Act, 2013, and the ICDR Regulations containing, *inter-alia*, the Offer Price, the size of the Offer and certain other information, including any addenda or corrigenda thereto;

“Qualified Institutional Buyers” or “QIBs” shall have the meaning given to such term under the SEBI (ICDR) Regulations, 2018.




“Registrar” shall mean Bigshare Services Private Limited

“Retail Applicants” shall mean individual applicants (includes HUFs and NRIs) who have applied for equity shares for an amount not more than Rs. 2,00,000, in any of the application options in the Offer.

“SEBI” shall mean the Securities and Exchange Board of India.

“SEBI (ICDR) Regulations 2018” shall mean the SEBI (Issue of Capital and Disclosure Requirements) Regulations 2018, as amended and as applicable to the Offering.

“Stock Exchange” shall mean NSE Limited.

<p>For Zenith Drugs Limited <b>For Zenith Drugs Limited,</b>  Director. Sandeep Bhardwaj Managing Director DIN: 00539347</p>	<p>For Gretex Corporate Services Limited  Alok Harlalka Managing Director DIN: 02486575</p>	<p>For Gretex Share Broking Limited  Alok Harlalka Director DIN: 02486575</p>
---	---	--

“Underwriters” shall mean Gretex Corporate Services Limited, a company incorporated under the Companies Act, 1956 and having its registered office at Office no. 13, 1st Floor, New Bansilal Building, Raja Bahadur Mansion, 9-15, Homi Modi Street, Fort, Mumbai – 400001, Maharashtra, India and Gretex Share Broking Limited a company incorporated under the Companies Act, 1956 and having its registered office at A-401, Floor 4th, Plot FP-616, (PT), Naman Midtown, Senapati Bapat Marg, Near Indiabulls Dadar (w) S V S Marg Mumbai 400028, Maharashtra, India

1.2 In this Agreement, unless the context otherwise requires:

- (a) word denoting the singular shall include the plural and vice versa;
- (b) words denoting a person shall include an individual, corporation, company, partnership, trust or other entity;
- (c) heading and bold typeface are only for convenience and shall be ignored for the purposes of interpretation;
- (d) references to the word “include” or “including” shall be construed without limitation;
- (e) references to this Issue Agreement or to any other agreement, deed or instrument shall be construed as a reference to this Issue Agreement or to such other agreement, deed, or instrument as the same may from time to time be amended, varied, supplemented or noted;
- (f) any reference to any Party to this Issue Agreement, or any other agreement, deed or instrument shall include its successors, heirs or permitted assigns;
- (g) references to a statute or statutory provision shall be construed as a reference to such provisions as from time to time amended, consolidated, modified, extended, re-enacted or replaced;
- (h) references to a Section, Paragraph or Annexure is, unless indicated to the contrary, a reference to a section, paragraph or annexure of this Issue Agreement; and






capitalized terms used in this Agreement and not specifically defined herein shall have the meanings given to such terms in the Draft Red Herring Prospectus and the Prospectus.

## 2. UNDERWRITING

On the basis of the representations and warranties contained in this Agreement and subjects to its terms and conditions, the Underwriters hereby agrees to underwrite and / or procure subscription for the Issue shares in the manner and on the terms and conditions contained elsewhere in of this Agreement and as mentioned below:




2.1 Following will be the underwriting obligations of each respective under:

Name of the Underwriter	No. of shares Underwritten	% of the Total Issue Size Underwritten
Gretex Corporate Services Limited	Upto [●]	Upto [●]
Gretex Share Broking Limited	Upto [●]	Upto [●]

<p>For Zenith Drugs Limited  <b>For Zenith Drugs Limited,</b>    <b>Director.</b>  Sandeep Bhardwaj  Managing Director  DIN: 00539347</p>	<p>For Gretex Corporate Services Limited    Alok Harlalka  Managing Director  DIN: 02486575  </p>	<p>For Gretex Share Broking Limited    Alok Harlalka  Director  DIN: 02486575  </p>
--	--	---

Total	Upto [●]	Upto [●]
-------	----------	----------

- 2.2 The Issuer Company shall before delivering to the Registrar of Companies (hereinafter referred to as "ROC") make available to the underwriters a copy of the Red Herring Prospectus, which shall be as modified in the light of the observations made by NSE while issuing the in-principal approval letter. The underwriters shall before execute their obligations under this agreement satisfy themselves with the terms of the offer and other information and disclosures contained therein.
- 2.3 The Company agrees that, if after filing of Prospectus with the ROC any additional disclosures are required to be made in the interest of the investors in regards to any matter relevant to the issue, the company shall with such requirements as may be stipulated by NSE or SEBI or the Book Running Lead Manager and compliance of such requirements shall be binding on the underwriter; provided that such disclosures shall not give a right to the underwriter to terminate or cancel its underwriting obligations unless such subsequent disclosures are certified by NSE or SEBI as being material in nature and essential for the contract of underwriting; the question whether or not such subsequent disclosures are material in nature, the decision of NSE or SEBI shall be final and binding on both the parties.
- 2.4 The subscription list for the public issue shall open not later than three months from the date of this agreement or such extended period(s) as the underwriters may agree to in writing. The subscription list shall be kept open by the company for a minimum period of 3 working days and if required by the underwriter, the same may be kept open upto a maximum of 10 calendar days failing which the underwriter shall not be bound to discharge the underwriting obligations under this agreement.
- 2.5 The application bearing the stamp of the underwriter or as the case may be the sub-underwriter whether made on their own behalf or otherwise shall be treated in the same manner as the applications received directly from the members of the public and, in the event of the offer being oversubscribed, such applications shall be treated on par with those received from the public and under no circumstances, the applications bearing the stamp of the underwriter or the sub-underwriter shall be given any preference or priority in the matter of allotment of the offer shares.
- 2.6 There is no provision for inter-changeability of the underwriting obligation i.e. GRETEX & GSBL shall have to underwrite their respective obligations as stated in 2.1 of this agreement and that they shall not be allowed to interchange any portion of the said obligations. All the applications made by any applicant except by GRETEX & GSBL in its "OWN" account shall be construed to be part of the "Net Issue" applications. In case of shortage in any of the specific portion (i.e. Market Maker Reservation Portion and the Net Issue Portion), the other Underwriter shall not be liable for any damages or losses as long as it has completed its individual obligations stated in 2.1 of this agreement.
- 2.7 Hence, w.r.t the Market Maker Reservation Portion, it is compulsory that the Market Maker i.e. Gretex Share Broking Limited subscribe to the specific portion of the Issue set aside as "Market maker Reservation Portion" as it needs to be subscribed in its own account in order to claim compliance with the requirements of Regulation 261 of the SEBI (ICDR) Regulations, 2018 as amended from time to time. Hence, it is prudent that Gretex Share Broking Limited ensure that its portion of equity shares is subscribed prior to the Closure of the Issue and that there are no relevant shortages in the same.
- 2.8 Only the Underwriter for the "Net Issue" shall be entitled to arrange for sub-underwriting of its underwriting obligation on his own account with any person or persons on term to be agreed upon between them. Notwithstanding such arrangement, the Underwriters shall be primarily responsible for

<p>For Zenith Drugs Limited, <b>For Zenith Drugs Limited,</b></p>  <p><b>Director,</b></p> <p>Sandeep Bhardwaj Managing Director DIN: 00539347</p>	<p>For Gretex Corporate Services Limited</p>  <p>Alok Harlalka Managing Director DIN: 02486575</p>	<p>For Gretex Share Broking Limited</p>  <p>Alok Harlalka Director DIN: 02486575</p>
---	--	---

sub-underwriting and any failure or default on the part of the sub-underwriters to discharge their respective sub-underwriting obligations, shall not exempt or discharge the underwriter of his underwriting obligation under this agreement.

2.9 If the Net Issue is undersubscribed, GRETEX & GSBL being the Underwriters for such portion shall be responsible to subscribe/ procure subscription to the unsubscribed shares. However, provided that such obligation shall not exceed the amount mentioned in clause 2.1 above.

2.10 The said underwriting obligations for each underwriter in case of shortage in its respective portions shall be discharged in the manner mentioned below:




- a) the Company shall within 3 days after the date of closure of subscription list communicate in writing to the respective underwriter, the total number of shares remaining unsubscribed, the number of shares required to be taken up by the underwriter or subscription to be procured therefore by the underwriter.
- b) the Company shall make available to the respective underwriter, the manner of computation of underwriting obligation and also furnish a certificate in support of such computation from the company's auditors.
- c) the respective underwriter on being satisfied about the extent of devolvement of the underwriting obligation, shall immediately and in any case not later than 30 days after receipt of the communication under sub-clause (a) above, in the manner specified in clauses 2.7, 2.8 and elsewhere in this agreement, make or procure the applications to subscribe to the shares and submit the same together with the application moneys to the Company in its Public Issue Account opened specifically for this Issue.
- d) in the event of failure of the underwriter to make the application to subscribe to the shares as required under clause (c) above, the Company shall be free to make arrangements with one or more persons to subscribe to such shares without prejudice to the rights of the Company to take such measures and proceedings as may be available to it against the underwriter including the right to claim damage for any loss suffered by the Company by reason of failure on the part of the underwriter to subscribe to the shares as aforesaid.

2.11 The Company is free to quantify the damage being a multiple of the value of the shares not subscribed by the respective underwriter.

### 3. REPRESENTATIONS AND WARRANTIES BY THE UNDERWRITERS

3.1 **Net worth of the Underwriter.** The underwriter(s), hereby declares that they satisfy the Net Worth/ Capital Adequacy Requirements specified under the SEBI (Underwriter) Rules and Regulations, 1993 or the bye-laws of the stock exchange of which the underwriter is a member and that he is competent to undertake the underwriting obligations mentioned in clause 2 hereinabove.

3.2 **Registration with the SEBI:** The underwriter(s) hereby declares that the underwriters being Merchant Banker or stock Brokers are entitled to carry on the business as an underwriter without obtaining a separate certificate under the SEBI (Underwriters) Regulations 1993 framed under the SEBI Act.

<p>For Zenith Drugs Limited <b>For Zenith Drugs Limited,</b>  <b>Director.</b> Sandeep Bhardwaj Managing Director DIN: 00539347</p>	<p>For Gretex Corporate Services Limited  Alok Harlalka Managing Director DIN: 02486575</p>	<p>For Gretex Share Broking Limited  Alok Harlalka Director DIN: 02486575</p>
--	---	--

3.3 The Underwriters confirm to the Company that they are responsible and liable to the Company, for any contravention of the SEBI Act, rules or regulations thereof. The Underwriters further confirm that they shall abide with their duties, function, responsibilities and obligations under the SEBI (Merchant Bankers) Regulations, 1992 and the SEBI (Underwriters) Regulations 1993.

3.4 In addition to any representations of the Underwriter(s) under the Regulation of Document filed with EMERGE Platform of National Stock Exchange of India Limited, the Underwriter(s) hereby represents and warrants that:

- a) It has taken all necessary actions to authorize the signing and delivery of this agreement;
- b) The signing and delivery of this agreement and the compliance with this agreement does not violate any law, rule, regulation or agreement, document or instrument binding on or applicable to the Underwriter.
- c) It will comply with all of its respective obligations set forth in this Agreement.
- d) It shall ensure compliance with the applicable laws and rules laid down by the SEBI and the EMERGE Platform of National Stock Exchange of India Limited w.r.t underwriting in general and underwriting this Public Issue in specific.
- e) It shall follow fair trade practices and abide by the code of conduct and ethics standards specified by SEBI, Stock Exchanges and other related associations from time to time.




3.5 The Underwriter(s) acknowledge that it is under a duty to notify the Issuer Company the EMERGE Platform of National Stock Exchange of India Limited immediately in case it become aware of any breach of a representation or warranty

#### 4. REPRESENTATIONS AND WARRANTIES BY THE ISSUER COMPANY

4.1 **Warranty as to statutory and other approvals.** The Company warrants that all consent, sanctions, clearance, approvals, permissions, licenses, etc., in connection with the public issue as detailed in the prospectus or required for completing the prospectus have been obtained or will be obtained and the same shall remain effective and in force until the allotment of all the shares/ debenture are completed.

4.2 In addition to any representations of the Issuer under the Prospectus the Issuer Company hereby represents and warrants that:

- a) It has taken all necessary actions to authorize the signing and delivery of this agreement;
- b) The signing and delivery of this agreement and the compliance with this agreement does not violate any law, rule, regulation or agreement, document or instrument binding on or applicable to the Issuer Company.
- c) It will comply with all of its respective obligations set forth in this Agreement.
- d) It shall ensure compliance with the applicable laws and rules laid down by the SEBI and the EMERGE Platform of National Stock Exchange of India Limited with respect to the role of the

<p>For Zenith Drugs Limited <b>For Zenith Drugs Limited,</b>  Director. Sandeep Bhardwaj Managing Director DIN: 00539347</p>	<p>For Gretex Corporate Services Limited  Alok Harlalka Managing Director DIN: 02486575</p>	<p>For Gretex Share Broking Limited  Alok Harlalka Director DIN: 02486575</p>
---	---	--

Issuer Company in the Market Making process in general and Market Making in the shares of **Zenith Drugs Limited**, in specific.

- e) It shall follow fair trade practices and abide by the code of conduct and ethics standards specified by SEBI, Stock Exchanges and other related associations from time to time.

4.3 The Issuer Company acknowledges that it is under a duty to notify the Underwriters and the EMERGE Platform of National Stock Exchange of India Limited immediately in case it becomes aware of any breach of a representation or a warranty.




## 5. CONDITIONS OF THE UNDERWRITERS' OBLIGATIONS

5.1 The several obligations of the Underwriter(s) under this agreement are subject to the following conditions:

- a) Subsequent to the execution and delivery of this Agreement and prior to the Issue Closing Date there shall not have occurred any regulatory changes, or any development involving a prospective regulatory changes or any order or directive from SEBI, the EMERGE Platform of National Stock Exchange of India Limited or any other governmental, regulatory or judicial authority that, in the judgment of the Underwriter(s), is material and adverse and that makes its, in the judgment of the Underwriter(s), impracticable to carry out Underwriter(s) obligations.
- b) Subsequent to the execution and delivery of this Agreement and prior to the Issue Closing Date there shall not have occurred any change, or any development involving a prospective changes, in the condition, financial or otherwise, or in the earnings, business, management, properties or operations of the Company and its subsidiaries, taken as a whole, that, in the judgment of the BRLM, is material and adverse and that makes it, in the judgment of BRLM, impracticable to market the Issue Shares on the terms and in the manner contemplated in the Issue Documents.
- c) If the Underwriter(s) are so notified or become aware of any such filing, communication, occurrence or event, as the case may be, they may give notice to the company to the effect, with regard to the Issue shares this agreement shall terminate and cease to have effect, subject as set out herein.
- d) The representations and warranties of the Issuer Company contained in this Agreement shall be true and correct on and as of the Issue Closing Date and that the Issuer Company shall have complied with all the conditions and obligations under this Agreement and the Issue Agreement dated July 18, 2023 on its part to be performed or satisfied on or before the Issue Closing Date.

5.2 If any condition specified in Section 5.1 shall not have been fulfilled when and as required to be fulfilled, this agreement may be terminated by the Underwriter(s) by written notice to the Issuer Company any time on or prior to the Issue Closing Date; provided, however, that this Section 5.2, Sections 3, 4, 7, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 and 20 shall survive the termination of this Agreement.

5.3 The Issuer Company shall not bear any other expense or losses, if any, incurred by the Underwriters in order to fulfill their respective Obligations, except for the fees/commissions etc. as mutually agreed.

<p>For Zenith Drugs Limited <b>For Zenith Drugs Limited,</b>  Director. Sandeep Bhardwaj Managing Director DIN: 00539347</p>	<p>For Gretex Corporate Services Limited  Alok Harlalka Managing Director DIN: 02486575</p>	<p>For Gretex Share Broking Limited  Alok Harlalka Director DIN: 02486575</p>
---	---	--

## 6. INDEMNITY




The Underwriters herein (GRETEX & GSBL) shall indemnify and keep indemnified the Issuer for its own account and their respective Affiliates and all the respective directors, Officers, employees, duly authorised agent and controlling persons (each, an "Indemnified Party") from and against any and all losses, liabilities, costs, Claims, charges, actions, proceedings, damages, expenses or demands which they (or any of them) incur or which is made against them (or any of them) as a result of the or arising out of, or in relation to the IPO subscription, trading, liquidity and failure to make minimum market requirement from time to time which are determined by a court or arbitral tribunal of competent jurisdiction to have resulted from any bad faith, dishonesty, illegal or fraudulent acts or the willful defaults or gross negligence on the part of the underwriters. Such indemnity will extend to include all reasonable costs, charges and expenses that such Indemnified Party may pay or incur in disputing or defending any such loss, liability, cost, claim, charges, demand or action or other proceeding.

The Issuer Company shall indemnify and keep indemnified, each of the Book Running Lead Manager, Underwriters and Market Makers for its own account and their respective Affiliates and all other respective directors, officers, employees, professionals, duly authorised agents and controlling persons (each, an "Indemnified Party") from against any and all losses, Liabilities, costs, claims, charges, actions, proceedings, damage, expenses or demands which they (or any of the them) incur or which is made against them (or any of them) as a result of or arising out of, or in relation to, any misrepresentation or alleged misrepresentation of a material fact contained in the draft red herring prospectus and prospectus or omission or alleged omission there from of a material fact necessary in order to make the statements therein in the light of the circumstances under which they were made not misleading, or which are determined by the court or arbitral tribunal of competent jurisdiction to have resulted from bad faith, dishonesty, illegal or fraudulent acts or the willful default or gross negligence on the part of the company. Such indemnity will extend to include all reasonable costs, charges and other expenses that such Indemnified party may pay or incur in disputing or defending any such loss, liability, cost, claim, charge, demand or action or other proceedings. Provided however that the issuer company and Selling Shareholders will not be liable to the Book Running lead manager, underwriters, Market Makers to the extent that any loss, claim, damage or liability is found in a judgment by the court to have resulted solely and directly from any of the Underwriters severally, as the case may be, bad faith or gross negligence or willful misconduct, illegal or Fraudulent acts, in performing the services under this agreement.

## 7. TERMINATIONS

7.1 Notwithstanding anything contained herein, the underwriter(s) shall have the option to be exercised by him at any time prior to the opening of the issue as notified in the prospectus of terminating this agreement under any or all of the following circumstances –

- i. if any representations/ statement made by the Company to the underwriter and/ or in the application forms, negotiations, correspondence, the prospectus or in this letter are or are found to be incorrect;
- ii. a complete breakdown or dislocation of business in the major financial markets, affecting major cities of India;
- iii. declaration of war or occurrence of insurrection, civil commotion or any other serious or sustained financial, political or industrial emergency or disturbance affecting the major financial markets of India.

<p>For Zenith Drugs Limited <b>For Zenith Drugs Limited,</b>  Director. Sandeep Bhardwaj Managing Director DIN: 00539347</p>	<p>For Gretex Corporate Services Limited  Alok Harlalka Managing Director DIN: 02486575</p>	<p>For Gretex Share Broking Limited  Alok Harlalka Director DIN: 02486575</p>
---	---	--

7.2 Notwithstanding anything contained in section 7.1 above, in the event of the Company failed to perform all or any of the covenants within limit specified wherever applicable under this letter of underwriting, the underwriter shall inform the Company with adequate documentary evidence of the breach/non-performance by Registered post/ Speed post and acknowledge obtained therefore, whereupon the underwriter shall be released from all or any of the obligations required to be performed by him.

7.3 The provision of Section 3, 4, 7, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 and 19 shall survive the termination of this agreement.

## 8. NOTICES

Any notice or other communication given pursuant to this Agreement must be in writing and (a) delivered personally, (b) sent by tele facsimile or other similar facsimile transmission, (c) or sent by registered mail, postage prepaid, address of the Party specified in the recitals to this Agreement, or to such fax number as may be designated in writing by such Party. All notices and other communications required or permitted under this agreement that are addressed as provided in this section will (i) if delivered personally or by overnight courier, be deemed given upon delivery; (ii) if delivery by tele facsimile or similar facsimile or similar facsimile transmission, be deemed given when electronically confirmed; and (iii) if sent by registered mail, be deemed given when electronically confirmed.

## 9. TIME IS THE ESSENCE OF AGREEMENT

All obligations of the Company and the Underwriters, are subject to the condition that time wherever stipulated, shall be of the essence of the Agreement. Consequently, any failure on the part of the Company or the Underwriter to adhere to the time limits shall unless otherwise agreed between the Company and the Underwriter, discharge the Underwriter or Company of his / their obligation under the Underwriting Agreement. The agreement shall be in force from the date of execution and will expire on completion of allotment for this Issue.




## 10. SEVERAL OBLIGATIONS

The Issuer Company and the Underwriter(s) acknowledge and agrees that they are all liable on a several basis to each other in respect of the representations, warranties, indemnities, undertakings and other obligations given, entered into or made by each of them in this Agreement.

## 11. MISCELLANEOUS

The Agreement shall be binding on and inure to the benefit of the Parties hereto and their respective successors. The Underwriter(s) shall not assign or transfer any of its respective rights or obligations under this Agreement or purport to do so without the consent of the Issuer Company. The Issuer Company shall not assign or transfer any of their respective rights or obligations under this Agreement or purport to do so without the consent of the Underwriter(s).

## 12. GOVERNING LAW AND JURISDICTION

<p>For Zenith Drugs Limited <b>For Zenith Drugs Limited,</b>  <b>Director.</b> Sandeep Bhardwaj Managing Director DIN: 00539347</p>	<p>For Gretex Corporate Services Limited  Alok Harlalka Managing Director DIN: 02486575</p>	<p>For Gretex Share Broking Limited  Alok Harlalka Director DIN: 02486575</p>
--	---	--



This Agreement shall be governed by and construed in accordance with the laws of the Republic of India and shall be subject to Indore jurisdiction.

### 13. ARBITRATION

**Reference to arbitration** - Any dispute arising out of this agreement between the underwriter and the Issuer Company shall be referred to the Arbitration Committee by the NSE in which the share is to be listed and the decision of the Arbitration Committee shall be final and binding on both the parties.

All proceedings in any such arbitration shall be conducted under the Arbitration and Conciliation Act, 1996, as amended, and shall be conducted in English. The arbitration shall take place in Indore, Maharashtra, India.

Any reference of any dispute, difference or claim to arbitration under this Agreement shall not affect the performance by the Parties of their respective obligations under this Agreement other than the obligations relating to the dispute, difference or claim referred to arbitration.

### 14. AMENDMENT

No amendment, supplement, modification or clarification to this Agreement shall be valid or binding unless set forth in writing and duly executed by all the Parties to this Agreement.

### 15. SEVERABILITY

If any provision or any portion of a provision of this Agreement is determined to be invalid or unenforceable in whole or in part, such invalidity or unenforceable shall attach only to such provision or the applicable part of such provision and the remaining part of such provision and all other provisions of this Agreement shall continue to remain in full force and effect.

### 16. COUNTERPARTS

This Agreement may be executed in separate counterparts, each of which when so executed and delivered shall be deemed to be an original, but all such counterparts shall constitute one and the same instrument.




### 17. CUMULATIVE REMEDIES

The rights and remedies of each of the parties and each indemnified person under Sections 8 and 9 pursuant to this Agreement are cumulative and are in addition to any other rights and remedies provided by general law or otherwise.

### 18. ILLEGALITY

If any provision in this Agreement shall be held to be illegal, invalid or unenforceable, in whole or in part, under any enactment or rule of law, such provision or part shall to that extent be deemed not to form part of this Agreement but the legality, validity and enforceable of the remainder of this Agreement shall not be affected.









### 19. ASSIGNMENT

<p>For Zenith Drugs Limited <b>For Zenith Drugs Limited,</b>  <b>Director,</b> Sandeep Bhardwaj Managing Director DIN: 00539347</p>	<p>For Gretex Corporate Services Limited  Alok Harlalka Managing Director DIN: 02486575</p>	<p>For Gretex Share Broking Limited  Alok Harlalka Director DIN: 02486575</p>
--	---	--

No party may assign any of its rights under this Agreement without the consent of the Party against whom the right operates. No provision of this Agreement may be varied without the consent of the Book Running Lead Manager.

The undersigned hereby certifies and consents to act as Book Running Lead Manager or Underwriter (as the case may be) to the aforesaid Issue and to their name being inserted as Book Running Lead Manager or Underwriter (as the case may be) in the Draft Red Herring Prospectus, Prospectus and Memorandum of Understanding which the Issuer Company intends to Issue in respect of the proposed Issue and hereby authorize the Issuer Company to deliver this Agreement to SEBI and the EMERGE Platform of National Stock Exchange of India Limited.

IN WITNESS WHEREOF the Parties have entered into this Agreement on the date mentioned above.

<p>For and on behalf of <b>For Zenith Drugs Limited</b></p> <p style="text-align: center;"><b>For Zenith Drugs Limited,</b>  <b>Director.</b></p> <hr/> <p>Sandeep Bhardwaj Managing Director DIN: 00539347</p>	<p><b>Witness</b> Name: <b>NIKHIL PATEL,</b> Address: <b>Shree Ram colony Ram, Indore</b> Signature </p>
<p>For and on behalf of <b>Gretex Corporate Services Limited</b></p> <p style="text-align: center;"> </p> <hr/> <p>Mr. Alok Harlalka Managing Director DIN: 02486575</p>	<p><b>Witness</b> Name: <b>Aashika Khosasia</b> Address: <b>Mumbai.</b> Signature </p>
<p>For and on behalf of <b>Gretex Share Broking Limited</b></p> <p style="text-align: center;"> </p> <hr/> <p>Mr. Alok Harlalka Director DIN: 02486575</p>	<p><b>Witness</b> Name: <b>Drashti Jhaveri</b> Address: <b>Mumbai</b> Signature </p>

<p>For Zenith Drugs Limited <b>For Zenith Drugs Limited,</b>  <b>Director.</b></p> <p>Sandeep Bhardwaj Managing Director DIN: 00539347</p>	<p>For Gretex Corporate Services Limited</p> <p style="text-align: center;"> </p> <p>Alok Harlalka Managing Director DIN: 02486575</p>	<p>For Gretex Share Broking Limited</p> <p style="text-align: center;"> </p> <p>Alok Harlalka Director DIN: 02486575</p>
---	---	--